Centurion CDO III Ltd. Note Ratings Withdrawn May 11

  • ID: 1805945
  • May 2011
  • Standard & Poors
1 of 3


  • Centurion CDO III Ltd.
  • MORE

NEW YORK (Standard & Poor's) May 26, 2011--Standard & Poor's Ratings Services today withdrew its rating on the class I notes from Centurion CDO III Ltd., a collateralized bond obligation (CBO) transaction. At the same time, we withdrew the rating on the class II notes. The rating was previously on CreditWatch with positive implications (see list). The rating actions follow the complete paydown of the notes on the most recent payment date of April 11, 2011. RELATED CRITERIA AND RESEARCH Principles Of Credit Ratings, published Feb. 16, 2011. Update To Global Methodologies And Assumptions For Corporate Cash Flow And Synthetic CDOs, published Sept. 17, 2009. General Criteria: Understanding Standard & Poor's Rating Definitions, published June 3, 2009. Update To General...

Companies mentioned in this report are: Centurion CDO III Ltd.
Action: Removed From CreditWatch
Action: Upgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Centurion CDO III Ltd.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.